SEALSQ and IC'Alps Advance Chip-Level Post-Quantum Security for Connected Medical Devices
iMTC Technology selected QVault TPM183 for its medical mouse in September 2026, adding a disclosed healthcare customer commitment.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SEALSQ (NASDAQ: LAES) outlined chip-level post-quantum security options for connected medical devices with its subsidiary IC'Alps, including custom chip development.
The options combine standard security chips with QASIC, a custom application-specific integrated circuit platform targeted for 2026. Post-quantum cryptography is designed to resist quantum-computer attacks. QS7001 V1 passed its technical security evaluation; V2 evaluation is expected in January 2027, with formal certification targeted for 2027. VaultIC409 engineering samples are planned for Q2 2027. QVault engineering samples are available, with certification of the full post-quantum TPM185 version targeted for May 2027. VaultIC408 has FIPS 140-3 Level 3 validation for conventional cryptography.
The technologies target new and next-generation products, not devices already in service. SEALSQ and IC'Alps plan live medical demonstrations at Electronica in Munich on November 10–13, 2026.
Positive
- Minor pointiMTC Technology selected QVault TPM183 for its Fingerprint Recognition Medical Mouse in September 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.QASIC's first platform is targeted for 2026, combining SEALSQ security with IC'Alps custom chip design.
- Minor pointQS7001 V1 completed its Common Criteria EAL5+ technical evaluation with a PASS.
- Minor pointQVault engineering samples are available.
- Minor point. Forward-looking: it has not happened yet and may not happen.VaultIC409 engineering samples are planned for Q2 2027.
- Minor pointVaultIC408 is FIPS 140-3 Level 3 validated for conventional cryptographic functions.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.QS7001 formal certification remains targeted for 2027; V2 evaluation is expected January 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.QVault TPM185 TCG certification remains targeted for May 2027 for the full post-quantum version.
- Minor pointDeployment scope covers new and next-generation products; devices already in service still require separate security measures.
- Minor pointLarger post-quantum keys and signatures must fit implants' and wearables' strict power and size limits.
Key Figures
- IoMT devices supporting PQC
- 6% vs. 50% of IT devices
- Devices using SSH implementations that support PQC
- Exposed medical information systems
- More than 5,500
- Identified by Forescout
- TLS 1.3 adoption
- 31%
- Average across internet-exposed medical information systems
- QS7001 V1 technical evaluation
- PASS
- Common Criteria EAL5+ evaluation completed
- QS7001 V2 evaluation
- January 2027
- Evaluation expected
- QS7001 formal certification
- 2027
- Certification targeted
- VaultIC409 engineering samples
- Q2 2027
- Samples planned
- QVault TPM185 TCG certification
- May 2027
- Certification targeted
Key Terms
post-quantum cryptography technical
asic technical
tls 1.3 technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Geneva, Switzerland, Nov. 09, 2026 (GLOBE NEWSWIRE) --
Post-quantum secure elements, Trusted Platform Modules and custom ultra-low-power ASICs address the IoMT security readiness gap, with live medical demonstrations at Electronica 2026.
SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today outlined how SEALSQ and its subsidiary IC'Alps can help manufacturers build post-quantum cryptography (PQC) into next-generation Internet of Medical Things (IoMT) devices at the chip level.
The initiative addresses a significant post-quantum readiness gap in connected healthcare. Forescout Research – Vedere Labs, reported by The HIPAA Journal found that only
A Readiness Gap Where Patient Care Depends on It
Forescout analyzed more than 2.5 million devices across more than 50 healthcare delivery organizations. Its findings show that the devices hardest to upgrade are often the ones hospitals rely on most for patient care:
- Medical devices lag:
6% of IoMT devices and16% of operational technology devices use SSH implementations that support PQC, against50% of IT devices. - Exposed systems lag too: Forescout identified more than 5,500 internet-exposed medical information systems. On average,
31% use TLS 1.3, the only TLS version that supports standardized PQC. - Key clinical systems are affected: TLS 1.3 use stands at
33% for electronic medical record systems,36% for picture archiving systems and13% for laboratory management systems.
The risk is immediate because attackers can harvest encrypted data now and decrypt it once quantum computers are powerful enough. Forescout notes that patient data stays valuable for a lifetime and cannot be reset like a payment card. The report also frames PQC as a patient-safety issue. Cryptography protects commands sent to devices, device telemetry, medication orders and firmware signatures.
Forescout classes regulated medical devices as low-agility assets, where a cryptographic change can depend on vendor release cycles, recertification or even hardware replacement. That makes device design the most effective point at which to act. Medical devices can remain in service for 10 to 20 years, so a design started today must be ready for the cryptography of the next two decades.
Executive Commentary
"Patient data stays sensitive for a lifetime, and a medical device can stay in service for many years," said Carlos Moreira, Founder, Chairman and CEO of SEALSQ. "That is why post-quantum security has to be designed in at the chip stage, not added once a device is on the market. The Forescout findings show how wide the gap is today. Together, SEALSQ and IC'Alps give manufacturers a practical way to close it in the devices they design next."
“Our experience designing ASICs for active implantable medical devices has taught us to address patient safety, reliable operation and long battery life together, from the earliest design decisions,” said Jean-Luc Triouleyre, Managing Director and Co-Founder of IC'Alps. “We bring that track record in ultra-low-power design and power management to QASIC, integrating SEALSQ’s post-quantum security alongside sensing and processing while addressing the stringent energy constraints of implants, within the ISO 13485 quality framework our medical customers rely on.”
From Standard Secure Chips to Custom Medical ASICs
SEALSQ and IC'Alps give manufacturers two routes: standard post-quantum chips designed into a product, or a custom ASIC with post-quantum security built in. Both implement the NIST-standardized ML-KEM (FIPS 203) and ML-DSA (FIPS 204) algorithms.
| Medical need | Technology | What it provides | Status |
| Implantable, wearable and patient-monitoring devices | QASIC by IC'Alps | Custom ASIC design and supply combining SEALSQ post-quantum security with IC'Alps analog, mixed-signal and ultra-low-power design | First platform targeted for 2026 |
| Secure communications and firmware integrity | QS7001 secure element | Hardware Root of Trust with ML-KEM, ML-DSA and classical cryptography; flash-based architecture for secure firmware updates | Common Criteria EAL5+ technical evaluation of V1 completed with a PASS; V2 evaluation expected January 2027; formal certification targeted for 2027 |
| Connected devices and gateways | VaultIC409 secure element | Quantum-ready Root of Trust built on QS7001, with cryptographic agility and a TLS 1.3 demonstration at electronica | Engineering samples planned for Q2 2027 |
| Device identity, secure boot and attestation | QVault TPM | Trusted Platform Module that generates and keeps ML-DSA and ML-KEM keys on-chip, alongside RSA and ECC | Engineering samples available; TCG certification targeted for May 2027 (TPM185, the full post-quantum version) |
| Protecting devices with conventional cryptography today | VaultIC408 secure element | FIPS 140-3 Level 3 validated module (NIST Certificate No. 5463), covering conventional cryptographic functions | Validated |
IC'Alps brings the medical expertise that PQC alone cannot supply. Its ISO 13485-certified teams develop custom circuits for smart ultrasound probes, implantable cardiac devices, Holter monitors, intracranial pressure monitoring and brain-computer interfaces. IC’Alps also supports its customers along with the ISO 14971 specific risk management of their product.
That experience matters because post-quantum keys and signatures are larger than those of the cryptography they replace, while implants and wearables have strict limits on power and size. QASIC addresses these constraints at the semiconductor-design stage, when security can be designed alongside sensing, processing, safety and power management.
SEALSQ's healthcare work also reaches the clinician workstation. In September 2026, iMTC Technology selected the QVault TPM183 for its Fingerprint Recognition Medical Mouse, giving the product a hardware root of trust and a migration path to PQC.
Beyond chip-level security, SEALSQ offers Public Key Infrastructure (PKI) through its INeS PKI solution, enabling the issue of digital certificates to every element – the medical device, the physician base station, the cloud, the embedded application, the building network – and the certificate that signs every firmware. Provisioned at manufacturing and managed over the whole lifecycle of the device, these quantum-safe identities secure data connections and software updates, and ultimately patient data and life.
These technologies are intended for new and next-generation products. Devices already in service will continue to need the measures Forescout recommends, including network segmentation, TLS 1.3 enforcement and PQC gateways.
See It at electronica 2026
SEALSQ and IC'Alps will exhibit at Electronica 2026 in Munich from November 10 - 13, 2026 in Hall C6, Booth 670. The booth will run live demonstrations across applications including medical, and will present QS7001, VaultIC409, QVault TPM, QASIC and INeS ID.
On November 13, 2026 at 11:50 a.m. CET, SEALSQ will give the keynote "Embedding certified secure hardware to simplify migration to post-quantum security standards" at the Embedded Systems World Forum. To book a meeting, visit www.sealsq.com/electronica_2026.
About IC'ALPS
IC'ALPS, a SEALSQ Company, is your one-stop-shop ASIC partner. Based in France (Grenoble and Toulouse), the company provides customers with a complete offering for Application Specific Integrated Circuits (ASIC) and Systems on Chip (SoC) development from circuit specification, mastering design in-house, up to the qualification, and the management of the entire production supply chain. Its 90+ engineers' areas of expertise include analogic, digital and mixed-signal circuits (sensor/MEMS interfaces, ultra-low power consumption, power management, high-resolution converters, high voltage, signal processing, ARM and RISC-V based multiprocessors architectures, hardware accelerators) on technologies from mature 0.18 µm down to advanced 1.8 nm, and from multiple foundries (TSMC, GlobalFoundries, Intel Foundry, X-FAB, ams-OSRAM, STMicroelectronics, UMC, DBH, etc.). The company is active worldwide in medical, automotive, industrial, IoT, AI, mil-aero and digital identity & security sectors. IC'ALPS is ISO 9001:2015, ISO 13485:2016, EN 9100:2018, Common Criteria certified, IATF 16949-ready, member of TSMC Design Center Alliance (DCA), GlobalFoundries GlobalSolutions™ Partner, ams Osram Preferred Partner, X-FAB's partner network, Intel Foundry Accelerator Design Service and Value Chain Alliance (DSA+VCA) and DB HiTek.
About SEALSQ
SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.
SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.
For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.
Forward-Looking Statements
This communication expressly or implicitly contains certain forward-looking statements concerning SEALSQ Corp and its businesses. Forward-looking statements include statements regarding our business strategy, financial performance, results of operations, market data, events or developments that we expect or anticipate will occur in the future, as well as any other statements which are not historical facts. Although we believe that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates which are inherently subject to significant uncertainties and contingencies, many of which are beyond our control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include SEALSQ's ability to continue beneficial transactions with material parties, including a limited number of significant customers; market demand and semiconductor industry conditions; and the risks discussed in SEALSQ's filings with the SEC. Risks and uncertainties are further described in reports filed by SEALSQ with the SEC.
SEALSQ Corp is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
| SEALSQ Corp. Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@sealsq.com | SEALSQ Investor Relations (US) The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 Lena.cati@theequitygroup.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is SEALSQ developing with IC'Alps for medical-device security?
SEALSQ and IC'Alps offer standard post-quantum security chips and QASIC custom chip development for new medical devices. Both routes implement the NIST-standardized ML-KEM and ML-DSA algorithms. The first QASIC platform is targeted for 2026.
Has SEALSQ's QS7001 received formal security certification?
Formal certification is targeted for 2027, rather than completed. QS7001 V1 completed its Common Criteria EAL5+ technical evaluation with a PASS, and the V2 evaluation is expected in January 2027.
What security measures are recommended for medical devices already in service?
Recommended measures include network segmentation, TLS 1.3 enforcement and post-quantum cryptography gateways. These address existing devices separately from SEALSQ and IC'Alps technologies intended for new and next-generation products.